Verve Group’s Match2One Launches First Ever Shopify App Giving Merchants New Ways to Grow Revenue
Verve Group today announces that Match2One – its easy-to-use advertising platform for small-business eCommerce – has launched an app in Shopify, offering merchants a self-serve, free-to-install app for building, serving, optimising, and measuring programmatic ads.
Match2One’s app is the first easy-to-use platform to drive additional revenue for merchants using Shopify. The platform enables merchants to automate their campaigns and make the most of spend as they face the challenge of a weaker economy, but simultaneous opportunities with the fast-approaching holiday season and retail’s most important quarter.
With just a few clicks, a merchant can launch an advertising campaign to complement existing Google and Facebook budgets. Verve Group has given the power of the Open Internet that has been used by large brands to their small- and medium-sized brethren–just in time for the holidays.
The Match2One app in the Shopify App Store provides users with:
- Access to inventory across 93% of the open web
- Performance data and real-time optimisation solutions
- Connections to all major supply-side platforms (SSPs)
- Easy-to-use brand safety controls to ensure the best ad placements
- An effortless creative studio for any size ad, equipped with templates and animation capabilities
By allowing users to automate any form of advertising, the Match2One self-serve platform streamlines the typically labour-intensive and manual process of running digital campaigns for Shopify sellers.
Cost and complexity have created a high barrier to entry for programmatic advertising and pushed smaller businesses to depend on walled gardens, largely due to their accessibility and scale. However, the Match2One platform ensures merchants can successfully diversify ad spend and maintain greater control over their campaigns. It has been developed to help democratise programmatic and ensure all businesses can access the same inventory, without requiring prior programmatic experience or extensive marketing resources.
“Our self-serve app puts automation capabilities in the hands of advertisers who have previously been excluded from the programmatic landscape,” commented Mikael Kreuger, CEO of Match2One, part of Verve Group.
“Our mission is to truly empower all businesses to reach their desired audiences through efficient campaigns. With this in mind, Shopify merchants who install the app will receive a bonus in their account balance to support their ad budgets. We want to widen the adoption of programmatic and make it accessible to every business.”
In the short time that the app was put into the Shopify App Store, it has already reaped measurable returns. Alexander Eriksson at Boulevard49, a user of Match2One’s Shopify App added: “Match2One’s app does all the work for you, finding the right audience in the right place. Everything from building banner ads in the Creative Studio to following results is effortless. This is a true one-stop-shop for programmatic advertising.”
About Match2One (www.match2one.com)
A member of the Verve Group advertising technology ecosystem, Match2One was created with a sole mission in mind: to make programmatic technology readily available, be easy to use, accessible and transparent. Match2One’s advertising platform allows any user to create smart campaigns without prior knowledge, and its AI optimisation automates campaigns and delivers high results that improve over time. Founded in 2015 and with offices in Stockholm, London, Kiev and Sydney, Match2One serves thousands of independent advertisers in more than 80 countries across the globe.
About Verve Group (www.verve.com)
Verve Group has created a more efficient and privacy-focused way to buy and monetize advertising. Verve Group is an ecosystem of demand and supply technologies fusing data, media, and technology together to deliver results and growth to both advertisers and publishers–no matter the screen or location, no matter who, what, or where a customer is. With 22 offices across the globe and with an eye on servicing forward-thinking advertising customers, Verve Group’s solutions are trusted by more than 90 of the United States’ top 100 advertisers, 4,000 publishers globally, and the world’s top demand-side platforms. Verve Group is a subsidiary of Media and Games Invest (MGI).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221017005800/en/
Contact information
Michael Shmarak
312-919-9222
michael.shmarak@verve.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MRM Health Raises €55 Million Series B to Advance Best-in-Class Microbiome-Based Biotherapeutic Product Pipeline4.9.2025 08:00:00 EEST | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced the successful closing of a €55 million (US$64 million) Series B financing round. The round was led by French pharmaceutical group Biocodex and included strong participation from German-based ATHOS, as well as new investor BNP Paribas Fortis Private Equity and existing investors SFPIM, Ackermans & van Haaren (AvH), OMX Europe Venture Fund (OMX), Qbic II and VIB. Validation of Leadership Position in Microbiome-Based Therapeutics Proceeds will enable MRM Health to complete a Phase 2b clinical trial for its lead program MH002 in patients suffering from mild-to-moderate ulcerative colitis. MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD), with positive clinical da
Abbove Unveils “Mia”: Opening a New Chapter in Digital Wealth Planning in Europe4.9.2025 07:00:00 EEST | Press release
Abbove, the European platform for collaborative and family-centered wealth planning, announces today the launch of Mia, its new artificial intelligence agent. Used by more than 1,100 advisors and deployed to over 37,000 families across Europe, Abbove takes a major step forward in its mission to reimagine the wealth advisory experience in the digital age. Designed to enhance the capabilities of wealth advisors, family officers, and financial experts, Mia acts as an intelligent co-pilot. It simplifies the reading and analysis of complex estate documents, automatically extracts key information, and assists users in the understanding, enrichment, and structuring of wealth data. “The launch of Mia opens an entirely new functional AI vertical on our platform, unlocking near-infinite possibilities for future development. It’s a key milestone that brings us closer to our ambition of becoming the leading pan-European wealth planning platform.” — Guillaume Desclée, Founder & CEO of Abbove Native
Biocytogen Enters into Agreement with Merck, KGaA, Darmstadt, Germany to Advance Antibody-Conjugated Lipid-Based Delivery Solutions4.9.2025 03:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies and Merck KGaA, Darmstadt, Germany, a leading science and technology company, have entered into an evaluation and option agreement to advance the development of antibody-conjugated lipid-based delivery solutions for nucleic acid payloads, such as antibody-conjugated lipid nanoparticle (LNP). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903434045/en/ Under the terms of the agreement, Biocytogen will provide proprietary, fully human antibodies derived from its RenMice® platform for evaluation in Merck KGaA, Darmstadt, Germany’s antibody-conjugated LNP services. Merck KGaA, Darmstadt, Germany has been granted an exclusive option to acquire rights to selected antibody assets in return for fees and royalties on sales and su
OpZira, Inc. Launches to Advance Ophthalmic Diagnostics with Innovative Medical Device Portfolio3.9.2025 20:23:00 EEST | Press release
OpZira™, Inc., a forward-thinking ophthalmic medical device company founded on a legacy of research excellence, today announced its official formation. OpZira is dedicated to delivering innovative technologies that enhance the detection and monitoring of ocular disease, empowering clinicians with advanced diagnostic tools. OpZira’s creation follows Alcon’s acquisition of LumiThera (https://www.alcon.com/media-release/alcon-completes-acquisition-lumithera/) and its innovative Valeda® Light Delivery System, the first and only FDA-authorized treatment for dry age-related macular degeneration (AMD). As part of the transaction, LumiThera’s diagnostic product lines were spun off to LumiThera shareholders, leading to the establishment of OpZira, Inc. OpZira’s product portfolio includes: AdaptDx Pro® – A wearable dark adaptometer that leverages AI to ensure a consistent patient experience. Impaired dark adaptation speed, a key early indicator of rod-mediated dysfunction, is often among the fir
BTG Bioliquids and NanosTech Partner to Deliver End-to-End Advanced Biofuels Solution3.9.2025 19:19:00 EEST | Press release
BTG Bioliquids BV (BTL), a Netherlands-based leader in fast pyrolysis technology, and NanosTech Technology & Innovations Ltd. (NanosTech), a Canada-based catalyst development and manufacturing company, have signed a Memorandum of Understanding (MOU) to deliver a fully integrated solution to produce advanced, drop-in biofuels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903698730/en/ The partnership combines BTL’s proven fast pyrolysis technology, which converts sustainable biomass into bio-oil, with NanosTech’s proprietary Aquaprocessing (AQP) platform, which upgrades even the most challenging bio-oils into refinery-ready feedstocks to produce fuels such as sustainable aviation fuel (SAF), renewable diesel, and marine fuels. The two companies are now actively collaborating to determine the location in Canada and Europe for the new 500-barrel-per-day modular biorefinery system. This system can be deployed near the feeds
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom